Concert Pharmaceuticals Inc. (NASDAQ:CNCE) shares were up 3% during mid-day trading on Monday . The company traded as high as $11.92 and last traded at $11.83, with a volume of 61,043 shares traded. The stock had previously closed at $11.49.

A number of research analysts have issued reports on CNCE shares. Brean Capital reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research report on Saturday, April 30th. Zacks Investment Research upgraded Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Stifel Nicolaus started coverage on Concert Pharmaceuticals in a research report on Friday, July 1st. They set a “buy” rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.43.

The company has a 50 day moving average price of $11.51 and a 200-day moving average price of $13.02. The stock has a market cap of $262.59 million and a P/E ratio of 14.19.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.18. On average, analysts forecast that Concert Pharmaceuticals Inc. will post ($2.16) earnings per share for the current fiscal year.

In related news, CEO Roger D. Tung bought 19,610 shares of the company’s stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average cost of $10.55 per share, with a total value of $206,885.50. Following the acquisition, the chief executive officer now owns 538,965 shares in the company, valued at approximately $5,686,080.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned approximately 1.02% of Concert Pharmaceuticals worth $4,256,000 at the end of the most recent quarter.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.